Announcements
- INmune Bio, Inc. Completes Blinded Interim Analysis of Phase II Alzheimer’s Disease Trial
- INmune Bio Inc. to Join Russell 3000® Index
- INmune Bio Inc. to Report First Quarter 2024 Financial Results and Provide a Corporate Update on Thursday, May 9
- INmune Bio Inc. Provides Update on Two Patients from the Phase 1b Alzheimer’s Disease Trial who Continue to Receive XPro™ Under Compassionate Use for Over Three Years
- INmune Bio Inc. Completes First Cohort and Initiates Second Cohort of Phase 1/2 Study of INKmune™ Natural Killer Cell Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer
- INmune Bio Inc. Announces $9.7 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
- INmune Bio Inc. Announces 24-Month Stability Validation of XPro™ for Phase III Readiness and Commercial Supply Chain Modeling & Development of Novel Immunogenicity Assay
- INmune Bio Inc. Raises Approximately $4.8 Million in Gross Proceeds Through Registered Direct Offering with Officers, Employees and Directors Purchasing Approximately 20% of the Offering
- INmune Bio Inc. Presents Data on INB03’s Role as an Immune Check Point Modulator in the Treatment of High-Risk Breast Cancer at AACR 2024
- INmune Bio Inc. to Report Fourth Quarter 2023 Financial Results and Provide a Corporate Update on Thursday, March 28
More ▼
Key statistics
As of last trade, INmune Bio Inc (0Y2:BER) traded at 7.55, 21.77% above the 52 week low of 6.20 set on Nov 14, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 7.55 |
---|---|
High | 7.55 |
Low | 7.55 |
Bid | 7.20 |
Offer | 9.40 |
Previous close | 8.40 |
Average volume | 0.00 |
---|---|
Shares outstanding | 19.78m |
Free float | 13.41m |
P/E (TTM) | -- |
Market cap | 179.62m USD |
EPS (TTM) | -1.92 USD |
Data delayed at least 15 minutes, as of Jul 22 2024 07:37 BST.
More ▼